Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 22.47M P/E - EPS this Y 25.80% Ern Qtrly Grth -
Income -8.54M Forward P/E -1.03 EPS next Y -130.40% 50D Avg Chg -6.00%
Sales 57k PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 2.23 EPS next 5Y - 52W High Chg -60.00%
Recommedations 2.00 Quick Ratio 7.04 Shares Outstanding 36.32M 52W Low Chg 65.00%
Insider Own 19.16% ROA -52.34% Shares Float 25.54M Beta 1.58
Inst Own 14.57% ROE -101.84% Shares Shorted/Prior 34.06K/27.75K Price 0.78
Gross Margin 15.79% Profit Margin - Avg. Volume 27,970 Target Price -
Oper. Margin -3,798.25% Earnings Date Nov 12 Volume 7,416 Change -0.01%
About Entera Bio Ltd.

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Ltd. News
11/08/24 Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
11/08/24 Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
10/04/24 Are Medical Stocks Lagging Argenx (ARGX) This Year?
09/26/24 ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
09/25/24 Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
09/18/24 Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
09/02/24 Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
08/30/24 We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
08/20/24 Entera Bio to Participate in Upcoming Investor and Scientific Conferences
08/15/24 All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
08/09/24 Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
08/01/24 Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
07/23/24 3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
07/08/24 3 Meme Stocks That Can Surge by 200% Before 2025
07/02/24 3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
06/25/24 3 Meme Stocks to Buy on the Dip: June 2024
06/20/24 7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months
06/20/24 Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich
06/17/24 3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024
06/10/24 Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
ENTX Chatroom

User Image Moody_T Posted - 2 hours ago

$ENTX $EVGO $INM goooo

User Image GarbageLoverHere Posted - 11 hours ago

$ENTX

User Image GarbageLoverHere Posted - 3 days ago

$ENTX

User Image d_risk Posted - 1 week ago

$ENTX - Entera Bio - 10Q - Updated Risk Factors Risk factors updated to include increased geopolitical tensions, direct attacks from Iran, escalated conflicts with Hezbollah, and Israel-Hamas war impacts, with Moody's downgrading Israel's credit rating, affecting capital raising and share prices. https://d-risk.ai/ENTX/10-Q/2024-11-08

User Image fauxstocks Posted - 1 week ago

$ENTX anyone know the reason for the jump?

User Image GarbageLoverHere Posted - 2 weeks ago

$ENTX Keeps being garbage

User Image Thez1998 Posted - 1 month ago

$ENTX ESTE ESTE COMPARA ♥ GO UP!

User Image GarbageLoverHere Posted - 1 month ago

$ENTX

User Image liloleme4 Posted - 09/27/24

$ENTX Found this one the other day in my searches. I'm intrigued enough to add it to my portfolio. Wish I'd found it a year ago, but still seems to have good possibilities coming up and I've been looking for some newbies

User Image Kassianys Posted - 09/27/24

$ENTX 👀

User Image NEWBIGTECH Posted - 09/26/24

$OPK $ENTX

User Image NEWBIGTECH Posted - 09/26/24

$OPK $ENTX

User Image GarbageLoverHere Posted - 09/25/24

$ENTX Out again. Will wait to another jump to short short short

User Image tymtested Posted - 09/25/24

$ENTX I may have to buy a few shares

User Image DonCorleone77 Posted - 09/25/24

$ENTX $OPK Entera Bio, Opko Health provide update on PK/PD results of GLP-1/Glucagon Entera Bio (ENTX) and OPKO Health (OPK) announced topline pharmacokinetic/pharmacodynamic, PK/PD, results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin analog developed by OPKO and Entera's proprietary N-Tab technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss. Entera and OPKO have completed in vivo proof-of-concept PK/PD studies in rodent and pig models. The studies' objectives were met with oral OXM exhibiting significant systemic exposure following a single dose in both models. Furthermore, a favorable PK profile and bioavailability were shown with oral OXM. In the pig model, oral OXM achieved high plasma concentrations with prolonged systemic exposure, which is consistent with the reported half-life for semaglutide, the only approved oral GLP-1 analog.

User Image Stock_Titan Posted - 09/25/24

$ENTX Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders https://www.stocktitan.net/news/ENTX/entera-bio-and-opko-health-provide-update-on-pk-pd-results-of-oral-nse8p6wi8yqd.html

User Image jeremy50641 Posted - 09/24/24

$ENTX

User Image signaljumper Posted - 2 months ago

$ENTX will go back to the highs soon over 3 bucks

User Image GarbageLoverHere Posted - 2 months ago

$ENTX Nice, shorti g time getting closer

User Image Thez1998 Posted - 2 months ago

$ENTX FDA soon? January.

User Image Doozio Posted - 2 months ago

$EWTX n they did! Bahhht who gives a fook all da macro jabronis been SPOT. Only faatch 💣s shud kill 🧠⏰ from here. Scrabble $entx while YO at it CUZ it gonna be $lgnd ary during 🧠⏰♾️

User Image Doozio Posted - 2 months ago

$ENTX NOW it’s getting obviously obvious in 🧠⏰♾️. Let bang bro n 🙏 FOUR no faatch 💣s. Obviously

User Image savaboy Posted - 2 months ago

$ENTX We will see $2.25 on Monday and $3.00 by end of the week. They are a great takeover opportunity at these levels

User Image LS0602 Posted - 2 months ago

$ENTX

User Image johnpatrucci Posted - 2 months ago

$ENTX This will run hard and fast. Just a matter of time. Fairly new ipo as well:) Company is doing work and has a bright future. I really like this one.

User Image signaljumper Posted - 2 months ago

$ENTX chart breakout targets see green lines

User Image savaboy Posted - 2 months ago

$ENTX price target $10 from top analyst. To the moon, love supporting Israeli companies that are innovative and curing people

User Image EingeLTrade Posted - 2 months ago

Such a great day for $ENTX fam

User Image GarbageLoverHere Posted - 2 months ago

$ENTX Time to….

User Image CrypToJetSetter Posted - 2 months ago

$ENTX don’t be fooled. Always goes up 30% or so then falls back down. Happens every couple of months

Analyst Ratings
HC Wainwright & Co. Buy Sep 27, 24
HC Wainwright & Co. Buy Aug 12, 24
HC Wainwright & Co. Buy Jun 5, 24
HC Wainwright & Co. Buy May 14, 24
HC Wainwright & Co. Buy May 13, 24
HC Wainwright & Co. Buy Apr 2, 24
HC Wainwright & Co. Buy Dec 11, 23
HC Wainwright & Co. Buy Sep 13, 23
HC Wainwright & Co. Buy Sep 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Taitel Haya Director Director Jan 12 Buy 0.99 9,500 9,405 35,115 01/16/24
Taitel Haya Director Director Jan 10 Buy 0.77 7,615 5,864 25,615 01/11/24
LIEBERMAN GERALD M Director Director Dec 22 Buy 0.71 23,952 17,006 226,961 12/27/23
Toledano Miranda Jayne Chief Executive Offi.. Chief Executive Officer Dec 22 Buy 0.71 23,952 17,006 110,752 12/27/23
Taitel Haya Director Director Aug 22 Buy 0.6231 18,000 11,216 18,000 08/24/23
LIEBERMAN GERALD M Director Director Aug 21 Buy 0.5892 20,000 11,784 214,209 08/23/23
Ellis Sean Director Director Jul 21 Buy 1.638 14,900 24,406 32,100 07/25/22
LIEBERMAN GERALD M Director Director Jul 21 Buy 1.683 19,491 32,803 160,209 07/25/22
OSTROV GERALD M Director Director Jan 13 Buy 2.7378 10,000 27,378 10,000 01/25/22
Ratan Ramesh U.S.based CFO U.S.based CFO Jan 19 Buy 2.4364 10,000 24,364 10,000 01/24/22
JAMAS SPIROS Chief Executive Offi.. Chief Executive Officer Jan 18 Buy 2.85 10,000 28,500 10,000 01/24/22
Schwartz Phillip President of R&D President of R&D Jan 20 Buy 2.525 10,000 25,250 607,410 01/24/22
LIEBERMAN GERALD M Director Director Jan 18 Buy 2.8 2,800 7,840 2,200 01/24/22